<h4>Objective</h4>To evaluate the real-world efficacy and safety of cadonilimab (a bispecific antibody targeting PD-1 and CTLA-4) in combination with chemotherapy with or without bevacizumab for cervical cancer and to identify potential biomarkers.<h4>Methods</h4>This preliminary report analyzes the first 51 consecutive patients from a protocol-driven observational cohort initiating cadonilimab (≥2 cycles) between June 2022 and August 2025. Here, CTLA4 is linked to cervical carcinoma.